LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) is anticipated to release its earnings data after the market closes on Thursday, February 27th. Analysts expect LeMaitre Vascular to post earnings of $0.49 per share and revenue of $55.99 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Shares of NASDAQ LMAT opened at $103.15 on Thursday. The firm has a fifty day moving average price of $96.04 and a 200-day moving average price of $93.92. The stock has a market cap of $2.32 billion, a PE ratio of 56.37, a price-to-earnings-growth ratio of 2.17 and a beta of 0.96. LeMaitre Vascular has a 1 year low of $59.87 and a 1 year high of $109.58.
Several research firms recently weighed in on LMAT. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $94.63.
View Our Latest Stock Report on LMAT
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.